Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BMF antisense RNA 1 (BMF-AS1)
- Target
- BMF-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA gene
01
Overview
BMF antisense RNA 1 (BMF-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the Bcl-2 modifying factor (BMF) gene. It is involved in regulating BMF expression at the post-transcriptional level and thereby modulates cellular apoptosis, vascular calcification, and cell senescence under disease conditions such as chronic obstructive pulmonary disease and diabetes. BMF-AS1 exerts its effects by stabilizing or enhancing BMF mRNA and protein expression, with knockdown of BMF-AS1 leading to reduced apoptosis and attenuation of vascular aging in disease models. There is no evidence BMF-AS1 is a direct target of any approved drugs; it is an emerging disease-relevant molecular regulator with potential as a diagnostic biomarker or future therapeutic target for RNA-targeting approaches.
- Other names
- Long non-coding RNA BMF-AS1LncRNA BMF-AS1RP11-521C20.3
02
Mechanism of action
BMF-AS1 modulates BMF mRNA stability/expression, with downstream effects on apoptosis and cellular aging. No known small molecule or biologic drug mechanism exists; however, RNA interference or antisense oligonucleotides could be potential approaches for targeting.
03
Biological functions
Regulation of apoptosis (by modulating BMF mRNA levels)Regulation of gene expression (antagonizes BMF mRNA stability and/or translation)Promotion of calcification and senescence in vascular smooth muscle cells (under high glucose/diabetic conditions)
04
Disease associations
Chronic obstructive pulmonary disease (COPD) (anti-apoptosis function in disease context)Diabetes/diabetic vascular calcification and agingPotential broader roles in cancer and other diseases involving apoptosis or cellular aging (by analogy to other antisense lncRNAs, but not yet firmly established for BMF-AS1 specifically)
05
Safety considerations
No direct therapeutic use and thus no clinical safety concerns currentlyOff-target effects would be a challenge for RNA-targeted therapeuticsDelivery challenges for RNA-targeted therapeutics
06
Biomarkers
Expression levels of BMF-AS1 as a potential biomarker for COPD and possibly for diabetic vascular calcification/aging; further studies needed for validation
Beyond the preview
Go deeper on BMF antisense RNA 1 (BMF-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMF antisense RNA 1 (BMF-AS1).